Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeti...
March 11 2021 - 8:00AM
Business Wire
Incyte (Nasdaq:INCY) today announced that multiple abstracts
from across its oncology portfolio will be presented during Week 1
of the upcoming American Association for Cancer Research (AACR)
Annual Meeting 2021, held virtually from April 10-15, 2021.
“At AACR 2021, we look forward to sharing clinical and
pre-clinical data from INCB106385, our novel A2A/A2B adenosine
receptor antagonist, and INCA00186, our novel CD73 monoclonal
antibody—both of which highlight our ongoing efforts targeting the
adenosine pathway. Presentations at the congress will also feature
updated data from our LIMBER development program, including results
from our Phase 2 combination study of ruxolitinib, a janus kinase
(JAK1/JAK2) inhibitor, and parsaclisib, a potent, highly selective
oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ),”
said Steven Stein, M.D., Chief Medical Officer, Incyte, adding, “We
further look forward to sharing clinical and pre-clinical data on
these and other targeted and immuno-oncology therapies in the
Incyte portfolio.”
Key abstracts from Incyte-sponsored and partner programs
include:
Targeted Therapy
Addition of Parsaclisib (INCB050465), a PI3Kδ Inhibitor, in
Patients with Suboptimal Response to Ruxolitinib: A Phase 2 Study
in Patients with Myelofibrosis (Abstract #CT162, Session: Phase
II Clinical Trials.)
The LSD1 Inhibitor INCB059872 is a Possible Therapeutic
Option for Venetoclax-Resistant AML (Abstract #1134, Session:
Epigenetic Targets.)
Accurate Detection of MET Exon 14 Skipping Using Liquid
Biopsy Assay in NSCLC Patients in the GEOMETRY Mono-1 Study1
(Abstract # LB056, Session: Liquid Biopsies: Circulating DNA.)
Immuno-Oncology
Discovery and Preclinical Characterization of INCB106385, a
Novel A2A/A2B Adenosine Receptor Antagonist, as a Cancer
Immunotherapy (Abstract #LB157, Session: Immune
Checkpoints.)
Discovery and Preclinical Characterization of INCA00186, a
Humanized Monoclonal Antibody Antagonist of CD73, as a Cancer
Immunotherapy (Abstract #LB174, Session: Therapeutic
Antibodies, Including Engineered Antibodies.)
All presentation sessions will be available on demand beginning
April 10, 2021 at 8:30 a.m. ET, through June 21, 2021. Full session
details and listings for oral and e-poster presentations are
available online via the AACR 2021 program:
https://www.abstractsonline.com/pp8/#!/9325.
About Incyte Incyte is a Wilmington, Delaware-based,
global biopharmaceutical company focused on finding solutions for
serious unmet medical needs through the discovery, development and
commercialization of proprietary therapeutics. For additional
information on Incyte, please visit Incyte.com and follow
@Incyte.
Forward-Looking Statements Except for the historical
information set forth herein, the matters set forth in this press
release, including statements regarding the presentation of data
from the Company’s or partner company’s ongoing clinical
development pipeline, and whether or when any development compounds
or combinations will be approved or commercially available for use
in humans anywhere in the world outside of the already approved
indications in specific regions, its presentation plans for the
upcoming AACR meeting and its goal of improving the lives of
patients, contain predictions, estimates and other forward-looking
statements.
These forward-looking statements are based on the Company’s
current expectations and subject to risks and uncertainties that
may cause actual results to differ materially, including
unanticipated developments in and risks related to: unanticipated
delays; further research and development and the results of
clinical trials possibly being unsuccessful or insufficient to meet
applicable regulatory standards or warrant continued development;
the ability to enroll sufficient numbers of subjects in clinical
trials and the ability to enroll subjects in accordance with
planned schedules; the effects of the COVID-19 pandemic and
measures to address the pandemic on the Company’s clinical trials,
supply chain and other third-party providers, and development and
discovery operations; determinations made by the FDA and other
regulatory authorities outside of the United States; [the Company’s
dependence on its relationships with its collaboration partners;]
and other risks detailed from time to time in the Company’s reports
filed with the Securities and Exchange Commission, including its
annual report on Form 10-K for the year ended December 31, 2020.
The Company disclaims any intent or obligation to update these
forward-looking statements.
1 Novartis-sponsored abstract.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210311005271/en/
Media Catalina Loveman +1 302 498 6171
cloveman@incyte.com
Investors Christine Chiou +1 302 274 4773
cchiou@incyte.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jul 2024 to Aug 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Aug 2023 to Aug 2024